HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in ChinaGlobeNewsWire • 09/12/23
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric CancerGlobeNewsWire • 08/29/23
HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in ChinaGlobeNewsWire • 08/21/23
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration StudyGlobeNewsWire • 07/20/23
Wall Street Analysts Think HUTCHMED (HCM) Could Surge 141.13%: Read This Before Placing a BetZacks Investment Research • 07/19/23
HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in ChinaGlobeNewsWire • 07/10/23
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The LancetGlobeNewsWire • 06/16/23
HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML MeetingsGlobeNewsWire • 06/09/23
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority ReviewGlobeNewsWire • 05/25/23
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board CommitteesGlobeNewsWire • 05/10/23
Wall Street Analysts See a 103.84% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?Zacks Investment Research • 04/26/23
HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric CancerGlobeNewsWire • 04/18/23
HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023GlobeNewsWire • 04/12/23
Wall Street Analysts Think HUTCHMED (HCM) Could Surge 102.73%: Read This Before Placing a BetZacks Investment Research • 04/10/23
HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA ConsultationsGlobeNewsWire • 04/04/23
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal CancerGlobeNewsWire • 03/31/23